Skip to content

Effect of ocular eletroacupuncture on diabetic oculomotor nerve palsy: a randomized clinical trial

Effect of ocular eletroacupuncture on diabetic oculomotor nerve palsy: a randomized clinical trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-15006012
Enrollment
Unknown
Registered
2015-02-26
Start date
2015-03-01
Completion date
Unknown
Last updated
2018-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic oculomotor nerve palsy

Interventions

The electroacupuncture group:Initial glucose-lowering therapy
electroacupuncture on extrocular muscle points.
The blank group:Initial glucose-lowering therapy

Sponsors

First Affiliated Hospital of Harbin Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Participants will be included if they fulfilled the following criteria: 1. A confirmed diagnosis of diabetic oculomotor nerve palsy by a ophthalmologist or neurologist; 2. With course of disease less than one month (30days); 3. To be aged 18 to 75 years old (both males and female patients are included) and 4. fully conscious and cooperative, voluntary to participate the trail and informed consent document has been signed.

Exclusion criteria

Exclusion criteria: Patients with any of the following conditions will be excluded: 1. history of Shy-Gonatas syndrome, congenital strabismus,high myopia,extrocular muscle epithesis; 2. complications of severe systematic diseases such as cardiocerebrovascular disease, liver or kidney disease, or unconsciousness; 3. severe infection or infection around eyes; 4. pregnancy or lactation; 5. mental disease; 6. severe contagious disease; 7. serious progressive disease (malignant tumor) or poor prognosis caused multiple failure; 8. known bleeding tendency (Hemostatic Disorders or blood coagulation disorders); taken therapeutic dose anticoagulant drug caused bleeding risk after acupuncture; 9. participating other clinical trail; 10. refuse to sign the informed consent document.

Design outcomes

Primary

MeasureTime frame
eyeball movement distance;diplopia angle;pupil;Palpebral fissure;health-related quality of life;

Countries

China

Contacts

Public ContactZhou lingyun
no1zhly@163.com+86 13351113936

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026